Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
← catalyst calendarSponsored by Exelixis (industry) · EXEL — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
837actual
Sites
245
Countries
Argentina, Australia, Austria +31
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-06-10 | actual | When the study began enrolling |
| Primary completion | 2021-11-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2018-11-28 | actual | When this record first appeared on the registry |
| Results posted | 2025-12-11 | actual | When the sponsor posted results to the registry |
| Record updated | 2025-12-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma
Interventions
- Drug: Cabozantinib — also filed as XL184, Cabometyx®
- Drug: Cabozantinib — also filed as XL184, Cabometyx®
- Drug: Sorafenib — also filed as Nexavar®
- Drug: Atezolizumab — also filed as Tecentriq®
Primary outcomes
what the primary-completion date above is the date OFProgression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population
measured From the date of first participant randomization up to 28 months
Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population
measured From the date of first participant randomization up to 36 months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-01-24 · 2.4 MB · Prot_000.pdf
Statistical Analysis Planposted 2021-02-05 · 2.3 MB · SAP_001.pdf
Publications
- PMID 38364832 — linked by the registry
- PMID 35798016 — linked by the registry
- PMID 32491932 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed